Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Liver

Towards omics-based risk assessment in NAFLD

A proteo-transcriptomic analysis of nonalcoholic fatty liver disease (NAFLD) uncovers biological pathways and potential biomarkers of high-risk disease. The work expands our understanding of the cellular origins of protein changes in NAFLD and translates them into an accurate diagnostic tool.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Proteo-transcriptomic map of steatohepatitis and advanced fibrosis translates to clinical risk prediction.

References

  1. Huang, D. Q. et al. Cell Metab. 34, 969–977 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Alvarez, C. S., Graubard, B. I., Thistle, J. E., Petrick, J. L. & McGlynn, K. A. Hepatology 72, 430–440 (2020).

    Article  CAS  PubMed  Google Scholar 

  3. Ludwig, J., Viggiano, T. R., McGill, D. B. & Oh, B. J. Mayo Clin. Proc. 55, 434–438 (1980).

    CAS  PubMed  Google Scholar 

  4. Sanyal, A. J. et al. N. Engl. J. Med. 385, 1559–1569 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ajmera, V. Hepatology 64, 309–310 (2016).

    Article  PubMed  Google Scholar 

  6. Govaere, O. et al. Nat. Metab. https://doi.org/10.1038/s42255-023-00775-1 (2023).

  7. Ajmera, V. & Loomba, R. Mol. Metab. 50, 101167 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Romeo, S. et al. Nat. Genet. 40, 1461–1465 (2008).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ratziu, V. et al. Gastroenterology 128, 1898–1906 (2005).

    Article  PubMed  Google Scholar 

  10. Ajmera, V. et al. Gastroenterology 163, 1079–1089 (2022).

    Article  PubMed  Google Scholar 

  11. Haas, M. E. et al. Cell Genom. 1, 100066 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sveinbjornsson, G. et al. Nat. Genet. 54, 1652–1663 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ajmera, V. et al. Aliment. Pharmacol. Ther. 54, 68–77, https://doi.org/10.1111/apt.16392 (2021).

  14. Verweij, N. et al. N. Engl. J. Med. 387, 332–344 (2022).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

V.A. is supported by NIDDK (K23DK119460).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Veeral Ajmera.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ajmera, V. Towards omics-based risk assessment in NAFLD. Nat Metab 5, 534–535 (2023). https://doi.org/10.1038/s42255-023-00772-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s42255-023-00772-4

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing